Lumos Diagnostics Holdings Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Douglas Ward
- Full Time Employees
- 29
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Suite 2, Level 11, 385 Bourke Street Melbourne VIC Australia 3000
- IPO Date
- Jul 5, 2021
- Website
- lumosdiagnostics.com
- Similar Companies
- Business
- Lumos Diagnostics Holdings Limited is a leader in developing and marketing swift, point-of-care diagnostic tests, primarily focusing on managing and identifying infectious diseases for healthcare systems in North America and Europe. The company delivers innovative solutions such as FebriDx, a diagnostic test designed to distinguish between bacterial and viral respiratory illnesses to support targeted treatment decisions, and ViraDx, a comprehensive three-in-one test for influenza A, influenza B, and COVID-19. Lumos also provides contract development and manufacturing services for customized diagnostic assays and offers its proprietary digital reader platforms. Established in 2004, the company maintains a presence in Melbourne, Australia, and Carlsbad, California. Notably, Lumos recently secured full U.S. Medicare reimbursement for its FebriDx test, enhancing its market penetration.
Company News
Lumos Diagnostics to provide US FebriDx update at quarterly results briefing
Lumos Diagnostics appoints Tenmile Ventures representative to board as US commercialisation advances
Nvidia Q2 earnings beat expectations with strong data center growth
FTSE 100 Live: Next and Glencore provide results boost, SpaceX tumbles
Tower Semiconductor tops second quarter earnings and revenue expectations
Lumos Diagnostics secures US$768,000 FebriDx order as US commercial rollout gathers pace
Small Cap watch: Pantoro hits spectacular gold and Lumos secures US order
Starbucks Q3 profit beats on US turnaround, lifts full-year guidance
Shell plans £3.1bn of buybacks as profits soar on higher oil prices
Lumos Diagnostics Holdings Limited (LDXHF) Q4 2026 Earnings Call Transcript
Cameco gets UBS upgrade on strengthening uranium bull case
Lumos Diagnostics caps FY26 with FebriDx revenue up 875% and US rollout gaining momentum
FTSE 100 Live: Stocks advance as oil price retreats, China's new chip champion IPOs
Nasdaq jumps as tech stocks revive, GM and 3M deliver earnings beats
Dow Jones closes above 52,000 for the first time as US-Iran truce holds
Lumos Diagnostics receives A$710,000 R&D tax rebate to support point-of-care technology development
Lumos Diagnostics Holdings Limited (LDXHF) Discusses Commercialisation Update and Market Strategy for FebriDx in the U.S. Transcript
US commercialisation of FebriDx® to be discussed at Lumos Webinar: Thursday, June 11, at 10:30am AEST
Five Below shares fall as tariff assumptions draw focus from earnings beat
FTSE 100 Live: Stocks vacillating, CMC surges, SpaceX to IPO next week